Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET
Company Participants
Jonae Barnes – Senior Vice President, Investor Relations & Corporate Communications
Jean-Pierre Sommadossi – Chief Executive Officer & Founder
Janet Hammond – Chief Development Officer
Arantxa Horga – Chief Medical Officer
Andrea Corcoran – Chief Financial Officer & Executive Vice President, Legal
Conference Call Participants
Bella Camaj – JPMorgan
Andy Hsieh – William Blair
Operator
Good afternoon, everyone, and welcome to the Atea Pharmaceuticals’ Fourth Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions.
I would now like to turn the call over to Jonae Barnes, Senior Vice President, Investor Relations and Corporate Communications at Atea Pharmaceuticals. Ms. Barnes, please proceed.
Jonae Barnes
Thank you, operator. Good afternoon everyone and welcome to Atea Pharmaceuticals’ fourth quarter and full year 2024 financial results and business update conference call. Earlier today, we issued a press release, which outlines the topics we plan to discuss. You can access the press release as well as the slides that we’ll be reviewing today by going to the Investors section of our website at ir.ateapharma.com.
With me today from Atea are Chief Executive Officer and Founder; Dr. Jean-Pierre Sommadossi; Chief Development Officer, Dr. Janet Hammond; John Vavricka, our Chief Commercial Officer; Dr. Arantxa Horga, our Chief Medical Officer; and Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran. They will all be available for the Q&A portion of today’s call.
Before we begin the call and as outlined on Slide 2, I would like to remind you that today’s discussion will contain forward-looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in
Be the first to comment